83 results
Page 2 of 5
424B5
fnip4rsd28
11 Sep 23
Prospectus supplement for primary offering
4:09pm
8-K
EX-99.1
8fq5ib3
11 Sep 23
Regulation FD Disclosure
6:05am
DEFA14A
ofkp1joh
27 Apr 23
Additional proxy soliciting materials
4:56pm
8-K
EX-99.1
nt3a0o spetc
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
dx9azxt4x8974w
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
424B5
szwo fyajy59cxsv
12 Aug 22
Prospectus supplement for primary offering
8:31am
DEFA14A
c3v4yxts7k1rb0c0n x9
28 Apr 22
Additional proxy soliciting materials
4:58pm
8-K
EX-1.1
00vg9 puwu4n1e
13 Apr 22
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
4:26pm
424B5
3q9 apccz
13 Apr 22
Prospectus supplement for primary offering
4:22pm
8-K
EX-99.1
8bchof 9obv
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm